Clovis Oncology Inc (NASDAQ:CLVS)

5.59
Delayed Data
As of Oct 23
 -0.04 / -0.71%
Today’s Change
2.93
Today|||52-Week Range
17.37
-46.43%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$528.8M

Company Description

Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of cancer treatments. Its marketed product Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is offered for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.

Contact Information

Clovis Oncology, Inc.
5500 Flatiron Parkway
Boulder Colorado 80301
P:(303) 625-5000
Investor Relations:
(303) 625-5023

Employees

Shareholders

Individual stakeholders5.12%
Mutual fund holders28.18%
Other institutional24.81%

Top Executives

Patrick J. MahaffyPresident, Chief Executive Officer & Director
Daniel W. MuehlChief Financial Officer & Executive Vice President
Lindsey RolfeChief Medical Officer & Executive VP-Clinical
Paul Edward GrossSecretary, Chief Compliance Officer & Executive VP
Gillian C. Ivers-ReadChief Regulatory Officer & Executive VP